1
|
Noufal MP, Widesott L, Sharma SD, Righetto R, Cianchetti M, Schwarz M. The Role of Plan Robustness Evaluation in Comparing Protons and Photons Plans - An Application on IMPT and IMRT Plans in Skull Base Chordomas. J Med Phys 2020; 45:206-214. [PMID: 33953495 PMCID: PMC8074721 DOI: 10.4103/jmp.jmp_45_20] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2020] [Revised: 10/17/2020] [Accepted: 10/30/2020] [Indexed: 12/03/2022] Open
Abstract
PURPOSE To analyze robustness of treatment plans optimized using different approaches in intensity modulated proton therapy (IMPT) and investigate the necessity of robust optimization and evaluation in intensity modulated radiotherapy (IMRT) plans for skull base chordomas. MATERIALS AND METHODS Two photon plans, standard IMRT and robustly optimized IMRT (RB-IMRT), and two IMPT plans, robustly optimized multi field optimization (MFO) and hybrid-MFO (HB-MFO), were created in RayStation TPS for five patients previously treated using single field uniform optimization (SFO). Both set-up and range uncertainties were incorporated during robust optimization of IMPT plans whereas only set-up uncertainty was used in RB-IMRT. The dosimetric outcomes from the five planning techniques were compared for every patient using standard dose volume indices and integral dose (ID) estimated for target and organs at risk (OARs). Robustness of each treatment plan was assessed by introducing set-up uncertainties of ±3 mm along the three translational axes and, only in protons, an additional range uncertainty of ±3.5%. RESULTS All the five nominal plans provided comparable and clinically acceptable target coverage. In comparison to nominal plans, worst case decrease in D95% of clinical target volume-high risk (CTV-HR) were 11.1%, 13.5%, and 13.6% for SFO, MFO, and HB-MFO plans respectively. The corresponding values were 13.7% for standard IMRT which improved to 11.5% for RB-IMRT. The worst case increased in high dose (D1%) to CTV-HR was highest in IMRT (2.1%) and lowest in SFO (0.7%) plans. Moreover, IMRT showed worst case increases in D1% for all neurological OARs and were lowest for SFO plans. The worst case D1% for brainstem, chiasm, spinal cord, optic nerves, and temporal lobes were increased by 29%, 41%, 30%, 41% and 14% for IMRT and 18%, 21%, 21%, 24%, and 7% for SFO plans, respectively. In comparison to IMRT, RB-IMRT improved D1% of all neurological OARs ranging from 5% to 14% in worst case scenarios. CONCLUSION Based on the five cases presented in the current study, all proton planning techniques (SFO, MFO and HB-MFO) were robust both for target coverage and OARs sparing. Standard IMRT plans were less robust than proton plans in regards to high doses to neurological OARs. However, robust optimization applied to IMRT resulted in improved robustness in both target coverage and high doses to OARs. Robustness evaluation may be considered as a part of plan evaluation procedure even in IMRT.
Collapse
Affiliation(s)
| | - Lamberto Widesott
- Department of Proton Therapy, Azienda Provinciale Per I Servizi Sanitari, Trento, Italy
| | | | - Roberto Righetto
- Department of Proton Therapy, Azienda Provinciale Per I Servizi Sanitari, Trento, Italy
| | - Marco Cianchetti
- Department of Proton Therapy, Azienda Provinciale Per I Servizi Sanitari, Trento, Italy
| | - Marco Schwarz
- Department of Proton Therapy, Azienda Provinciale Per I Servizi Sanitari, Trento, Italy
- TIFPA - INFN, Trento, Italy
| |
Collapse
|
2
|
Abstract
Denser ionisation clustering and complex DNA damage in proton Bragg peaks far exceeds that seen with conventional X-rays. This results in more efficient cell sterilisation, quantified by the relative biological effectiveness (RBE). Currently, a 1.1 RBE is used to determine the clinical proton doses by dividing the usual X-rays dose by this amount. This number, derived from short-term experiments, has been criticised as being irrelevant to late normal tissue (NT) effects following radiotherapy and included many control irradiations using lower voltage X-rays (with elevated RBE values) than those used in the clinic. In principle, an increased RBE could be used for each organ at risk, by using extensions of the clinically successful linear quadratic model. Protons undoubtedly reduce or eliminate NT radiation dose in tissues distantly located from a tumour, but the necessity to include NT margins around a tumour can result in a higher volume of NT than tumour being irradiated. Deleterious side-effects can follow if the NT RBE exceeds 1.1, including in tissue very close to these margins and which are only partially spared. Use of a constant 1.1 RBE can ‘overdose’ NT, which may require a greater dose reduction such as 1.2 in the brain; some tumours may be ‘under-dosed’ (since they might require a lesser or no reduction in dose). More sophisticated proton experiments show that RBE values of 1.1–1.5 and higher occur in some situations. There are now mathematical models of varying degrees of complexity that can estimate the RBE from the dose, LET and the low-LET radiosensitivities. True multidisciplinary cooperation is required to implement such new ideas in proton therapy in order to improve safety and effectiveness.
Collapse
Affiliation(s)
- Bleddyn Jones
- Gray Laboratory, CRUK/MRC Oxford Oncology Institute, The University of Oxford, ORCRB - Roosevelt Drive, Oxford OX3 7DQ, UK
| |
Collapse
|
3
|
Jones B. A Simpler Energy Transfer Efficiency Model to Predict Relative Biological Effect for Protons and Heavier Ions. Front Oncol 2015; 5:184. [PMID: 26322274 PMCID: PMC4531328 DOI: 10.3389/fonc.2015.00184] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2015] [Accepted: 07/27/2015] [Indexed: 01/26/2023] Open
Abstract
The aim of this work is to predict relative biological effectiveness (RBE) for protons and clinically relevant heavier ions, by using a simplified semi-empirical process based on rational expectations and published experimental results using different ion species. The model input parameters are: Z (effective nuclear charge) and radiosensitivity parameters αL and βL of the control low linear energy transfer (LET) radiation. Sequential saturation processes are assumed for: (a) the position of the turnover point (LETU) for the LET–RBE relationship with Z, and (b) the ultimate value of α at this point (αU) being non-linearly related to αL. Using the same procedure for β, on the logical assumption that the changes in β with LET, although smaller than α, are symmetrical with those of α, since there is symmetry of the fall off of LET–RBE curves with increasing dose, which suggests that LETU must be identical for α and β. Then, using iso-effective linear quadratic model equations, the estimated RBE is scaled between αU and αL and between βU and βL from for any input value of Z, αL, βL, and dose. The model described is fitted to the data of Barendsen (alpha particles), Weyrather et al. (carbon ions), and Todd for nine different ions (deuterons to Argon), which include variations in cell surviving fraction and dose. In principle, this new system can be used to complement the more complex methods to predict RBE with LET such as the local effect and MKM models which already have been incorporated into treatment planning systems in various countries. It would be useful to have a secondary check to such systems, especially to alert clinicians of potential risks by relatively easy estimation of relevant RBEs. In clinical practice, LET values smaller than LETU are mostly encountered, but the model extends to higher values beyond LETU for other purposes such as radiation, protection, and astrobiology. Considerable further research is required, perhaps in a dedicated international laboratory, using a basket of different models to determine what the best system or combination of systems will be to make proton and ion beam radiotherapy as safe as possible and to produce the best possible clinical results.
Collapse
Affiliation(s)
- Bleddyn Jones
- Gray Laboratory, CRUK/MRC Oxford Insitute for Radiation Oncology, University of Oxford , Oxford , UK
| |
Collapse
|
4
|
McGowan SE, Albertini F, Thomas SJ, Lomax AJ. Defining robustness protocols: a method to include and evaluate robustness in clinical plans. Phys Med Biol 2015; 60:2671-84. [PMID: 25768095 DOI: 10.1088/0031-9155/60/7/2671] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
We aim to define a site-specific robustness protocol to be used during the clinical plan evaluation process. Plan robustness of 16 skull base IMPT plans to systematic range and random set-up errors have been retrospectively and systematically analysed. This was determined by calculating the error-bar dose distribution (ebDD) for all the plans and by defining some metrics used to define protocols aiding the plan assessment. Additionally, an example of how to clinically use the defined robustness database is given whereby a plan with sub-optimal brainstem robustness was identified. The advantage of using different beam arrangements to improve the plan robustness was analysed. Using the ebDD it was found range errors had a smaller effect on dose distribution than the corresponding set-up error in a single fraction, and that organs at risk were most robust to the range errors, whereas the target was more robust to set-up errors. A database was created to aid planners in terms of plan robustness aims in these volumes. This resulted in the definition of site-specific robustness protocols. The use of robustness constraints allowed for the identification of a specific patient that may have benefited from a treatment of greater individuality. A new beam arrangement showed to be preferential when balancing conformality and robustness for this case. The ebDD and error-bar volume histogram proved effective in analysing plan robustness. The process of retrospective analysis could be used to establish site-specific robustness planning protocols in proton therapy. These protocols allow the planner to determine plans that, although delivering a dosimetrically adequate dose distribution, have resulted in sub-optimal robustness to these uncertainties. For these cases the use of different beam start conditions may improve the plan robustness to set-up and range uncertainties.
Collapse
Affiliation(s)
- S E McGowan
- Department of Oncology, University of Cambridge, Cambridge, UK
| | | | | | | |
Collapse
|
5
|
Grabham P, Sharma P. The effects of radiation on angiogenesis. Vasc Cell 2013; 5:19. [PMID: 24160185 PMCID: PMC3895662 DOI: 10.1186/2045-824x-5-19] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2013] [Accepted: 10/22/2013] [Indexed: 12/31/2022] Open
Abstract
The average human body contains tens of thousands of miles of vessels that permeate every tissue down to the microscopic level. This makes the human vasculature a prime target for an agent like radiation that originates from a source and passes through the body. Exposure to radiation released during nuclear accidents and explosions, or during cancer radiotherapy, is well known to cause vascular pathologies because of the ionizing effects of electromagnetic radiations (photons) such as gamma rays. There is however, another type of less well-known radiation - charged ion particles, and these atoms stripped of electrons, have different physical properties to the photons of electromagnetic radiation. They are either found in space or created on earth by particle collider facilities, and are of significant recent interest due to their enhanced effectiveness and increasing use in cancer radiotherapy, as well as a health risk to the growing number of people spending time in the space environment. Although there is to date, relatively few studies on the effects of charged particles on the vascular system, a very different picture of the biological effects of these particles compared to photons is beginning to emerge. These under researched biological effects of ion particles have a large impact on the health consequences of exposure. In this short review, we will discuss the effects of charged particles on an important biological process of the vascular system, angiogenesis, which creates and maintains the vasculature and is highly important in tumor vasculogenesis.
Collapse
Affiliation(s)
- Peter Grabham
- Center for Radiological research, Columbia University, VC 11-243, 630 West 168th street, New York, NY 10032, USA
| | - Preety Sharma
- Center for Radiological research, Columbia University, VC 11-243, 630 West 168th street, New York, NY 10032, USA
| |
Collapse
|
6
|
Tuan J, Vischioni B, Fossati P, Srivastava A, Vitolo V, Iannalfi A, Fiore MR, Krengli M, Mizoe JE, Orecchia R. Initial clinical experience with scanned proton beams at the Italian National Center for Hadrontherapy (CNAO). JOURNAL OF RADIATION RESEARCH 2013; 54 Suppl 1:i31-42. [PMID: 23824124 PMCID: PMC3700505 DOI: 10.1093/jrr/rrt036] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/08/2023]
Abstract
We report the initial toxicity data with scanned proton beams at the Italian National Center for Hadrontherapy (CNAO). In September 2011, CNAO commenced patient treatment with scanned proton beams within two prospective Phase II protocols approved by the Italian Health Ministry. Patients with chondrosarcoma or chordoma of the skull base or spine were eligible. By October 2012, 21 patients had completed treatment. Immobilization was performed using rigid non-perforated thermoplastic-masks and customized headrests or body-pillows as indicated. Non-contrast CT scans with immobilization devices in place and MRI scans in supine position were performed for treatment-planning. For chordoma, the prescribed doses were 74 cobalt grey equivalent (CGE) and 54 CGE to planning target volume 1 (PTV1) and PTV2, respectively. For chondrosarcoma, the prescribed doses were 70 CGE and 54 CGE to PTV1 and PTV2, respectively. Treatment was delivered five days a week in 35-37 fractions. Prior to treatment, the patients' positions were verified using an optical tracking system and orthogonal X-ray images. Proton beams were delivered using fixed-horizontal portals on a robotic couch. Weekly MRI incorporating diffusion-weighted-imaging was performed during the course of proton therapy. Patients were reviewed once weekly and acute toxicities were graded with the Common Terminology Criteria for Adverse Events (CTCAE). Median age of patients = 50 years (range, 21-74). All 21 patients completed the proton therapy without major toxicities and without treatment interruption. Median dose delivered was 74 CGE (range, 70-74). The maximum toxicity recorded was CTCAE Grade 2 in four patients. Our preliminary data demonstrates the clinical feasibility of scanned proton beams in Italy.
Collapse
Affiliation(s)
- J Tuan
- Department of Radiation Oncology, National Cancer Centre Singapore, 11 Hospital Drive, 169610, Singapore.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Saito S, Hasegawa S, Sekita A, Bakalova R, Furukawa T, Murase K, Saga T, Aoki I. Manganese-enhanced MRI reveals early-phase radiation-induced cell alterations in vivo. Cancer Res 2013; 73:3216-24. [PMID: 23695553 DOI: 10.1158/0008-5472.can-12-3837] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
For tumor radiotherapy, the in vivo detection of early cellular responses is important for predicting therapeutic efficacy. Mn(2+) is used as a positive contrast agent in manganese-enhanced MRI (MEMRI) and is expected to behave as a mimic of Ca(2+) in many biologic systems. We conducted in vitro and in vivo MRI experiments with Mn(2+) to investigate whether MEMRI can be used to detect cell alterations as an early-phase tumor response after radiotherapy. Colon-26 cells or a subcutaneously grafted colon-26 tumor model were irradiated with 20 Gy of X-rays. One day after irradiation, a significant augmentation of G2-M-phase cells, indicating a cell-cycle arrest, was observed in the irradiated cells in comparison with the control cells, although both early and late apoptotic alterations were rarely observed. The MEMRI signal in radiation-exposed tumor cells (R1: 0.77 ± 0.01 s(-1)) was significantly lower than that in control cells (R1: 0.82 ± 0.01 s(-1)) in vitro. MEMRI signal reduction was also observed in the in vivo tumor model 24 hours after irradiation (R1 of radiation: 0.97 ± 0.02 s(-1), control: 1.10 ± 0.02 s(-1)), along with cell-cycle and proliferation alterations identified with immunostaining (cyclin D1 and Ki-67). Therefore, MEMRI after tumor radiotherapy was successfully used to detect cell alterations as an early-phase cellular response in vitro and in vivo.
Collapse
Affiliation(s)
- Shigeyoshi Saito
- Department of Medical Physics and Engineering, Division of Medical Technology and Science, Faculty of Health Science, Graduate School of Medicine, Osaka University, Osaka, Japan
| | | | | | | | | | | | | | | |
Collapse
|
8
|
Controversies in Clinical Trials in Proton Radiotherapy: The Present and the Future. Semin Radiat Oncol 2013; 23:127-33. [DOI: 10.1016/j.semradonc.2012.11.004] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
|
9
|
Girdhani S, Sachs R, Hlatky L. Biological Effects of Proton Radiation: What We Know and Don't Know. Radiat Res 2013; 179:257-72. [DOI: 10.1667/rr2839.1] [Citation(s) in RCA: 104] [Impact Index Per Article: 9.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
10
|
McGowan SE, Burnet NG, Lomax AJ. Treatment planning optimisation in proton therapy. Br J Radiol 2013; 86:20120288. [PMID: 23255545 DOI: 10.1259/bjr.20120288] [Citation(s) in RCA: 63] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023] Open
Abstract
The goal of radiotherapy is to achieve uniform target coverage while sparing normal tissue. In proton therapy, the same sources of geometric uncertainty are present as in conventional radiotherapy. However, an important and fundamental difference in proton therapy is that protons have a finite range, highly dependent on the electron density of the material they are traversing, resulting in a steep dose gradient at the distal edge of the Bragg peak. Therefore, an accurate knowledge of the sources and magnitudes of the uncertainties affecting the proton range is essential for producing plans which are robust to these uncertainties. This review describes the current knowledge of the geometric uncertainties and discusses their impact on proton dose plans. The need for patient-specific validation is essential and in cases of complex intensity-modulated proton therapy plans the use of a planning target volume (PTV) may fail to ensure coverage of the target. In cases where a PTV cannot be used, other methods of quantifying plan quality have been investigated. A promising option is to incorporate uncertainties directly into the optimisation algorithm. A further development is the inclusion of robustness into a multicriteria optimisation framework, allowing a multi-objective Pareto optimisation function to balance robustness and conformity. The question remains as to whether adaptive therapy can become an integral part of a proton therapy, to allow re-optimisation during the course of a patient's treatment. The challenge of ensuring that plans are robust to range uncertainties in proton therapy remains, although these methods can provide practical solutions.
Collapse
Affiliation(s)
- S E McGowan
- Department of Oncology, University of Cambridge, Cambridge, UK.
| | | | | |
Collapse
|
11
|
Aitkenhead AH, Bugg D, Rowbottom CG, Smith E, Mackay RI. Modelling the throughput capacity of a single-accelerator multitreatment room proton therapy centre. Br J Radiol 2013; 85:e1263-72. [PMID: 23175492 DOI: 10.1259/bjr/27428078] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
Abstract
OBJECTIVE We describe a model for evaluating the throughput capacity of a single-accelerator multitreatment room proton therapy centre with the aims of (1) providing quantitative estimates of the throughput and waiting times and (2) providing insight into the sensitivity of the system to various physical parameters. METHODS A Monte Carlo approach was used to compute various statistics about the modelled centre, including the throughput capacity, fraction times for different groups of patients and beam waiting times. A method of quantifying the saturation level is also demonstrated. RESULTS Benchmarking against the MD Anderson Cancer Center showed good agreement between the modelled (140 ± 4 fractions per day) and reported (133 ± 35 fractions per day) throughputs. A sensitivity analysis of that system studied the impact of beam switch time, the number of treatment rooms, patient set-up times and the potential benefit of having a second accelerator. Finally, scenarios relevant to a potential UK facility were studied, finding that a centre with the same four-room, single-accelerator configuration as the MD Anderson Cancer Center but handling a more complex UK-type caseload would have a throughput reduced by approximately 19%, but still be capable of treating in excess of 100 fractions per 16-h treatment day. CONCLUSIONS The model provides a useful tool to aid in understanding the operating dynamics of a proton therapy facility, and for investigating potential scenarios for prospective centres. ADVANCES IN KNOWLEDGE The model helps to identify which technical specifications should be targeted for future improvements.
Collapse
Affiliation(s)
- A H Aitkenhead
- Christie Medical Physics and Engineering, The Christie NHS Foundation Trust, Manchester, UK.
| | | | | | | | | |
Collapse
|
12
|
Dosanjh M, Cirilli M, Greco V, Meijer AE. ENLIGHT: The European Network for Light Ion Hadron Therapy. HEALTH PHYSICS 2012; 103:674-680. [PMID: 23032898 DOI: 10.1097/hp.0b013e3182606520] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
The European Network for Light Ion Hadron Therapy (ENLIGHT) was established in 2002 to coordinate European efforts on hadron therapy (radiotherapy performed with protons and light ions instead of high-energy photons). The ENLIGHT network is formed by the European Hadron Therapy Community, with more than 300 participants from 20 different countries. A major success of ENLIGHT has been uniting traditionally separate communities so that clinicians, physicists, biologists, and engineers with experience and interest in particle therapy work together. ENLIGHT has been a successful initiative in forming a common European platform and bringing together people from diverse disciplines. ENLIGHT demonstrates the advantages of regular and organized exchanges of data, information, and best practices, as well as determining and following strategies for future needs in research and technological development in the hadron therapy field.
Collapse
Affiliation(s)
- Manjit Dosanjh
- CERN, European Organization for Nuclear Research, 1211 Geneva 23, Switzerland.
| | | | | | | |
Collapse
|
13
|
Wilson P, Jones B, Yokoi T, Hill M, Vojnovic B. Revisiting the ultra-high dose rate effect: implications for charged particle radiotherapy using protons and light ions. Br J Radiol 2012; 85:e933-9. [PMID: 22496068 PMCID: PMC3474025 DOI: 10.1259/bjr/17827549] [Citation(s) in RCA: 51] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2011] [Revised: 11/08/2011] [Accepted: 11/17/2011] [Indexed: 12/26/2022] Open
Abstract
OBJECTIVE To reinvestigate ultra-high dose rate radiation (UHDRR) radiobiology and consider potential implications for hadrontherapy. METHODS A literature search of cellular UHDRR exposures was performed. Standard oxygen diffusion equations were used to estimate the time taken to replace UHDRR-related oxygen depletion. Dose rates from conventional and novel methods of hadrontherapy accelerators were considered, including spot scanning beam delivery, which intensifies dose rate. RESULTS The literature findings were that, for X-ray and electron dose rates of around 10(9) Gy s(-1), 5-10 Gy depletes cellular oxygen, significantly changing the radiosensitivity of cells already in low oxygen tension (around 3 mmHg or 0.4 kPa). The time taken to reverse the oxygen depletion of such cells is estimated to be over 20-30 s at distances of over 100 μm from a tumour blood vessel. In this time window, tumours have a higher hypoxic fraction (capable of reducing tumour control), so the next application of radiation within the same fraction should be at a time that exceeds these estimates in the case of scanned beams or with ultra-fast laser-generated particles. CONCLUSION This study has potential implications for particle therapy, including laser-generated particles, where dose rate is greatly increased. Conventional accelerators probably do not achieve the critical UHDRR conditions. However, specific UHDRR oxygen depletion experiments using proton and ion beams are indicated.
Collapse
Affiliation(s)
- P Wilson
- Gray Institute of Radiation Oncology and Biology, Oxford, UK
| | | | | | | | | |
Collapse
|
14
|
Jones B, Underwood TSA, Carabe-Fernandez A, Timlin C, Dale RG. Fast neutron relative biological effects and implications for charged particle therapy. Br J Radiol 2012; 84 Spec No 1:S11-8. [PMID: 22374547 DOI: 10.1259/bjr/67509851] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
Abstract
In two fast neutron data sets, comprising in vitro and in vivo experiments, an inverse relationship is found between the low-linear energy transfer (LET) α/β ratio and the maximum value of relative biological effect (RBE(max)), while the minimum relative biological effect (RBE(min)) is linearly related to the square root of the low-LET α/β ratio. RBE(max) is the RBE at near zero dose and can be represented by the ratio of the α parameters at high- and low-LET radiation exposures. RBE(min) is the RBE at very high dose and can be represented by the ratio of the square roots of the β parameters at high- and low-LET radiation exposures. In principle, it may be possible to use the low-LET α/β ratio to predict RBE(max) and RBE(min, )providing that other LET-related parameters, which reflect intercept and slopes of these relationships, are used. These two limits of RBE determine the intermediate values of RBE at any dose per fraction; therefore, it is possible to find the RBE at any dose per fraction. Although these results are obtained from fast neutron experiments, there are implications for charged particle therapy using protons (when RBE is scaled downwards) and for heavier ion beams (where the magnitude of RBE is similar to that for fast neutrons). In the case of fast neutrons, late reacting normal tissue systems and very slow growing tumours, which have the smallest values of the low-LET α/β ratio, are predicted to have the highest RBE values at low fractional doses, but the lowest values of RBE at higher doses when they are compared with early reacting tissues and fast growing tumour systems that have the largest low-LET α/β ratios.
Collapse
Affiliation(s)
- B Jones
- Gray Institute for Radiation Oncology and Biology, University of Oxford, Headington, Oxford, UK.
| | | | | | | | | |
Collapse
|
15
|
Abstract
The use of cyclotrons and synchrotrons to accelerate charged particles in hospital settings for the purpose of cancer therapy is increasing. Consequently, there is a growing demand from medical physicists, radiographers, physicians and oncologists for articles that explain the basic physical concepts of these technologies. There are unique advantages and disadvantages to all methods of acceleration. Several promising alternative methods of accelerating particles also have to be considered since they will become increasingly available with time; however, there are still many technical problems with these that require solving. This article serves as an introduction to this complex area of physics, and will be of benefit to those engaged in cancer therapy, or who intend to acquire such technologies in the future.
Collapse
Affiliation(s)
- K Peach
- Particle Therapy Cancer Research Institute, Oxford Martin School, University of Oxford, Oxford, UK.
| | | | | |
Collapse
|
16
|
Dosanjh M, Jones B, Mayer R, Meyer R. ENLIGHT and other EU-funded projects in hadron therapy. Br J Radiol 2011; 83:811-3. [PMID: 20846982 DOI: 10.1259/bjr/49490647] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
Abstract
Following impressive results from early phase trials in Japan and Germany, there is a current expansion in European hadron therapy. This article summarises present European Union-funded projects for research and co-ordination of hadron therapy across Europe. Our primary focus will be on the research questions associated with carbon ion treatment of cancer, but these considerations are also applicable to treatments using proton beams and other light ions. The challenges inherent in this new form of radiotherapy require maximum interdisciplinary co-ordination. On the basis of its successful track record in particle and accelerator physics, the internationally funded CERN laboratories (otherwise known as the European Organisation for Nuclear Research) have been instrumental in promoting collaborations for research purposes in this area of radiation oncology. There will soon be increased opportunities for referral of patients across Europe for hadron therapy. Oncologists should be aware of these developments, which confer enhanced prospects for better cancer cure rates as well as improved quality of life in many cancer patients.
Collapse
|
17
|
The apparent increase in the {beta}-parameter of the linear quadratic model with increased linear energy transfer during fast neutron irradiation. Br J Radiol 2009; 83:433-6. [PMID: 20019177 DOI: 10.1259/bjr/68792966] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
Abstract
The issue of whether the beta-parameter of the linear quadratic model changes with linear energy transfer (LET) remains controversial. Retrospective analysis of UK fast neutron experimental data using human cell lines at Clatterbridge shows that the beta-parameter of the linear quadratic model probably does increase with LET during neutron irradiation. For cells without a deficiency in DNA damage repair and for experiments in which beta-parameter estimates were considered to be unreliably low, a provisional relationship of beta(H) = 1.82 beta(L) was found (where the suffixes refer to high and low LET exposures, respectively). This implies that radicalbeta increases by around 1.35 in the specific case of 62.5 MeV neutrons relative to 4 MeV X-rays. Increments in the beta-parameter with LET influence the relative biological effect (RBE), especially at high doses per fraction. Large fractions are being used in experimental carbon ion therapy, in which broadly similar RBE values to fast neutrons are found. These interesting findings after fast neutron exposure need to be studied further for applications in charged particle beam therapy using light ions, which is presently undergoing a worldwide expansion.
Collapse
|
18
|
Abstract
The clinical results of carbon ion therapy pioneered in Japan remain promising, especially in a wide range of cancers that are difficult to treat using X-rays. As well as producing impressive tumour control rates, there appears to be a marked reduction in radiation-related toxicity, as would be expected from the advantageous dose distributions. There remain some controversial research-related issues, such as the radiobiological conversion methods, dose fractionation, and which form of accelerator systems and treatment delivery systems should be used. Cost is a major issue, which is being addressed by the use of far fewer treatments than with X-ray therapy. The expansion of this form of treatment in Japan and mainland Europe will provide opportunities for a large research portfolio, which is necessary to optimise this kinder form of radiotherapy.
Collapse
|
19
|
Jones B. United Kingdom Radiation Oncology — Past, Present and Future. Clin Oncol (R Coll Radiol) 2009; 21:509-11. [DOI: 10.1016/j.clon.2009.05.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2009] [Accepted: 05/06/2009] [Indexed: 11/29/2022]
|
20
|
Jones B. Modelling carcinogenesis after radiotherapy using Poisson statistics: implications for IMRT, protons and ions. JOURNAL OF RADIOLOGICAL PROTECTION : OFFICIAL JOURNAL OF THE SOCIETY FOR RADIOLOGICAL PROTECTION 2009; 29:A143-A157. [PMID: 19454805 DOI: 10.1088/0952-4746/29/2a/s10] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
Abstract
Current technical radiotherapy advances aim to (a) better conform the dose contours to cancers and (b) reduce the integral dose exposure and thereby minimise unnecessary dose exposure to normal tissues unaffected by the cancer. Various types of conformal and intensity modulated radiotherapy (IMRT) using x-rays can achieve (a) while charged particle therapy (CPT)-using proton and ion beams-can achieve both (a) and (b), but at greater financial cost. Not only is the long term risk of radiation related normal tissue complications important, but so is the risk of carcinogenesis. Physical dose distribution plans can be generated to show the differences between the above techniques. IMRT is associated with a dose bath of low to medium dose due to fluence transfer: dose is effectively transferred from designated organs at risk to other areas; thus dose and risk are transferred. Many clinicians are concerned that there may be additional carcinogenesis many years after IMRT. CPT reduces the total energy deposition in the body and offers many potential advantages in terms of the prospects for better quality of life along with cancer cure. With C ions there is a tail of dose beyond the Bragg peaks, due to nuclear fragmentation; this is not found with protons. CPT generally uses higher linear energy transfer (which varies with particle and energy), which carries a higher relative risk of malignant induction, but also of cell death quantified by the relative biological effect concept, so at higher dose levels the frank development of malignancy should be reduced. Standard linear radioprotection models have been used to show a reduction in carcinogenesis risk of between two- and 15-fold depending on the CPT location. But the standard risk models make no allowance for fractionation and some have a dose limit at 4 Gy. Alternatively, tentative application of the linear quadratic model and Poissonian statistics to chromosome breakage and cell kill simultaneously allows estimation of relative changes in carcinogenesis that incorporate fractionation and relative biological effects (RBE). This alternative modelling approach allows absolute and relative risk estimations per cell and can be extended to tissues. The classical turnover point in carcinogenesis occurring after a single exposure is a feature of the model; also, the dose-response relationship becomes pseudo-linear with extended fractionation and when heterogeneity of the radiosensitivity parameters is introduced; there is also an inverse relationship between dose per fraction and cancer induction. In principle, this new approach might influence the conduct of proton and ion beam therapy, particularly beam placements and fractionation policies. The theoretical implications for future radiotherapy are considerable, but these predictions should be subjected to cellular and tissue experiments that simulate these forms of treatment, including any secondary neutron production in some cases depending on the beam delivery technique, e.g. in tissue equivalent humanoid phantoms using cell transformation techniques. Since the UK has no working high energy particle beam facility over 100 MeV, British scientists would require use of particle beam facilities in Europe, USA or Japan to perform experiments.
Collapse
Affiliation(s)
- Bleddyn Jones
- Gray Institute for Radiation Oncology and Biology, University of Oxford, Old Road Campus, Headington, Oxford OX3 7DQ, UK.
| |
Collapse
|
21
|
BURNET NG, KACPEREK A, GOODMAN SE, GREEN S. Proton and particle radiotherapy — a report on the Franco–British seminar on the future of cancer treatment and imaging using new physics-based technologies. Br J Radiol 2009; 82:183-9. [DOI: 10.1259/bjr/26414068] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
|
22
|
Toxicity after Cervical Cancer Treatment using Radiotherapy and Chemotherapy. Clin Oncol (R Coll Radiol) 2009; 21:56-63. [DOI: 10.1016/j.clon.2008.10.009] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2008] [Revised: 09/30/2008] [Accepted: 10/06/2008] [Indexed: 11/23/2022]
|